Spots Global Cancer Trial Database for adjuvant
Every month we try and update this database with for adjuvant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | NCT05382741 | Colorectal Canc... No Evidence of ... | Durvalumab Inje... Regorafenib 30 ... | 18 Years - | Ospedale Policlinico San Martino | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. | NCT03381066 | Completely Rese... | gefitinib, peme... Vinorelbine, ci... | 20 Years - | Yonsei University | |
| Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | NCT06089369 | Hepatocellular ... | Sintilimab (9 c... Sintilimab (18 ... Active surveill... | 18 Years - 75 Years | Tongji Hospital | |
| Predictive Assay for Decision Making in Adjuvant Therapy | NCT05032352 | Carcinoma, Non-... | Adjuvant Observation | 18 Years - | OncoCyte | |
| Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer | NCT01061359 | Breast Neoplasm | Epirubicin: Obs... | - | Pfizer | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients. | NCT01123434 | 2 Years PSA Rec... | 18 Years - | AstraZeneca | ||
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer | NCT00374322 | Neoplasms, Brea... | lapatinib placebo | 18 Years - | GlaxoSmithKline | |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | NCT01660711 | Pancreatic Aden... | 5 Fluorouracil Leucovorin Irinotecan Oxaliplatin | 18 Years - | NorthShore University HealthSystem | |
| Dose Dense TC + Pegfilgrastim Support for Breast Cancer | NCT01671319 | Female Breast C... | docetaxel + cyc... | 18 Years - | University of Wisconsin, Madison | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery | NCT02462681 | Acute Pain Chronic Pain | paravertebral b... | 25 Years - 70 Years | Assiut University | |
| Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | NCT04688801 | Esophageal Canc... Gastroesophagea... Immunotherapy Adjuvant | Chemotherapy Dr... Immunotherapy | 25 Years - 80 Years | The Second Hospital of Shandong University | |
| Arimidex Observational: Reason for and Effect of Change From Tamoxifen | NCT00246961 | Breast Cancer | 18 Years - | AstraZeneca | ||
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | NCT01508000 | Colorectal Canc... Liver Metastase... KRAS Wild Type ... | FOLFOX6 Bevacizumab Panitumumab Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model | NCT03263663 | Colo-rectal Can... RAS Wild-type UICC III UICC II + RF UICC IV Curativ... | targeted substa... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | NCT02967289 | Colon Cancer (H... | Irinotecan Folfox Protocol | 18 Years - 75 Years | UNICANCER | |
| IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | NCT02967289 | Colon Cancer (H... | Irinotecan Folfox Protocol | 18 Years - 75 Years | UNICANCER | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free | NCT01141491 | Sarcoma | Trivalent gangl... OPT-821 | 16 Years - | MabVax Therapeutics, Inc. | |
| Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI | NCT01425749 | Melanoma | recMAGE-A3 + AS... | 18 Years - | University of Virginia | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | NCT06384820 | Cutaneous Squam... | cemiplimab fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma | NCT05429138 | Melanoma | biological samp... | 18 Years - 45 Years | Assistance Publique Hopitaux De Marseille | |
| Various G-CSF Regimens to Prevent Infection During Chemotherapy | NCT00536081 | Breast Cancer Chemotherapy Febrile Neutrop... | pegfilgrastim | 18 Years - | Academisch Ziekenhuis Maastricht | |
| Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) | NCT06005818 | Renal Cell Carc... | Pembrolizumab i... | 18 Years - | University of Alabama at Birmingham | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) | NCT05925530 | Non-small Cell ... | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma | NCT05429138 | Melanoma | biological samp... | 18 Years - 45 Years | Assistance Publique Hopitaux De Marseille | |
| Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma | NCT05545969 | Mucosal Melanom... | Pembrolizumab Lenvatinib | 18 Years - 100 Years | Melanoma Institute Australia | |
| Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | NCT04688801 | Esophageal Canc... Gastroesophagea... Immunotherapy Adjuvant | Chemotherapy Dr... Immunotherapy | 25 Years - 80 Years | The Second Hospital of Shandong University | |
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer | NCT00463489 | Breast Cancer | Lifestyle inter... Mail-based | - | Ontario Clinical Oncology Group (OCOG) | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer | NCT05780736 | Esophageal Carc... Gastroesophagea... | 18 Years - | Bristol-Myers Squibb | ||
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | NCT04630730 | Bladder Cancer | Recombinant int... Atezolizumab Cisplatin Gemcitabine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | NCT01206296 | Pancreatic Aden... | Intraperitoneal... | 18 Years - | Medstar Health Research Institute | |
| A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer | NCT05780736 | Esophageal Carc... Gastroesophagea... | 18 Years - | Bristol-Myers Squibb | ||
| Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients. | NCT02718391 | Malignant Melan... Adjuvant Drug T... Vaccin Therapy | Autologous Dend... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment | NCT00126867 | Colon Cancer | 18 Years - | AHS Cancer Control Alberta | ||
| Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation | NCT02196961 | Merkel Cell Car... | Nivolumab | 18 Years - | University Hospital, Essen | |
| A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall | NCT00790244 | Soft Tissue Sar... Non Metastatic ... | doxorubicin , i... doxorubicin, if... doxorubicin, if... doxorubicin, if... | 18 Years - 75 Years | Oslo University Hospital | |
| Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model | NCT03263663 | Colo-rectal Can... RAS Wild-type UICC III UICC II + RF UICC IV Curativ... | targeted substa... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) | NCT05925530 | Non-small Cell ... | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
| Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | NCT00867113 | Gastrointestina... | imatinib mesyla... | 18 Years - | Novartis | |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | Metastatic Mela... | NEO-PV-01 Nivolumab Adjuvant APX005M ipilimumab | 18 Years - | BioNTech SE | |
| Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma | NCT05429138 | Melanoma | biological samp... | 18 Years - 45 Years | Assistance Publique Hopitaux De Marseille | |
| Various G-CSF Regimens to Prevent Infection During Chemotherapy | NCT00536081 | Breast Cancer Chemotherapy Febrile Neutrop... | pegfilgrastim | 18 Years - | Academisch Ziekenhuis Maastricht | |
| Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data | NCT06346821 | Glioblastoma Mu... | Optune® (Tumor ... | 18 Years - | Sichuan University | |
| Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen | NCT01965483 | Breast Neoplasm... | once-weekly bre... | 50 Years - | Instituto do Cancer do Ceara | |
| Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma | NCT00928902 | Melanoma | low-dose IL-2 melanoma vaccin... | 18 Years - 85 Years | University of Virginia | |
| Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. | NCT03983096 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | NCT03867084 | Hepatocellular ... | Pembrolizumab Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | NCT00525642 | Breast Neoplasm... Adjuvant Chemotherapy | Docetaxel, Doxo... Docetaxel, Doxo... | 18 Years - 70 Years | Fudan University | |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | NCT05907954 | Uveal Melanoma | Darovasertib | 18 Years - | IDEAYA Biosciences | |
| A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | NCT00789581 | Breast Cancer | Doxorubicin Cyclophosphamid... Ixabepilone (Ix... Paclitaxel (Tax... | 18 Years - | SCRI Development Innovations, LLC | |
| Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | NCT01401959 | Metastatic Brea... | Eribulin Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | NCT03617328 | Melanoma | 6MHP Montanide ISA-5... polyICLC CDX-1127 | 18 Years - | University of Virginia | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute | |
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | NCT04013854 | Melanoma Stage ... Melanoma | nivolumab Ipilimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Efficacy of Propranolol Treatment to Prevent Melanoma Progression | NCT01988831 | Stages III Skin... Stages II Skin ... Stage IB Skin M... | Propranolol hyd... Placebo pill | 18 Years - | University Hospital, Geneva | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab and Tremelimumab in Resectable HCC | NCT05440864 | Hepatocellular ... | Tremelimumab | 18 Years - | University Health Network, Toronto | |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | NCT03380871 | Carcinoma, Non-... Lung Cancer Nonsquamous Non... | NEO-PV-01 Pembrolizumab Adjuvant Carboplatin Pemetrexed | 18 Years - | BioNTech SE | |
| Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | NCT02650271 | Hepatocellular ... | Entecavir Tenofovir | 18 Years - 75 Years | Guangxi Medical University | |
| Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | NCT00563836 | Ovarian Cancer Epithelial Ovar... | Catumaxomab | 18 Years - | Neovii Biotech | |
| Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes | NCT02754180 | Pancreatic Neop... | Gemcitabine TS-1 with radia... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
| Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | NCT02650271 | Hepatocellular ... | Entecavir Tenofovir | 18 Years - 75 Years | Guangxi Medical University | |
| Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC | NCT00321334 | Non-small Cell ... | Chemotherapy+Su... | 18 Years - 75 Years | Chinese Society of Lung Cancer | |
| A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors | NCT00373425 | Non-small Cell ... | Erlotinib Placebo | 18 Years - | Astellas Pharma Inc | |
| Various G-CSF Regimens to Prevent Infection During Chemotherapy | NCT00536081 | Breast Cancer Chemotherapy Febrile Neutrop... | pegfilgrastim | 18 Years - | Academisch Ziekenhuis Maastricht | |
| Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | NCT01206296 | Pancreatic Aden... | Intraperitoneal... | 18 Years - | Medstar Health Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
